APA (7th ed.) Citation

I, W., WJA, W., SMAA, E., M, M., & M, H. (2026). Model-Based Economic Evaluation of the First-in-Class Myosin Inhibitor Mavacamten Versus Care as Usual in Obstructive Hypertrophic Cardiomyopathy Patients from a Dutch Societal Perspective. PharmacoEconomics, 44(2), 245. https://doi.org/10.1007/s40273-025-01564-2

Chicago Style (17th ed.) Citation

I, Wiethoff, Witlox WJA, Evers SMAA, Michels M, and Hiligsmann M. "Model-Based Economic Evaluation of the First-in-Class Myosin Inhibitor Mavacamten Versus Care as Usual in Obstructive Hypertrophic Cardiomyopathy Patients from a Dutch Societal Perspective." PharmacoEconomics 44, no. 2 (2026): 245. https://doi.org/10.1007/s40273-025-01564-2.

MLA (9th ed.) Citation

I, Wiethoff, et al. "Model-Based Economic Evaluation of the First-in-Class Myosin Inhibitor Mavacamten Versus Care as Usual in Obstructive Hypertrophic Cardiomyopathy Patients from a Dutch Societal Perspective." PharmacoEconomics, vol. 44, no. 2, 2026, p. 245, https://doi.org/10.1007/s40273-025-01564-2.